Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

571
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
571
Pleura of the Lungs01:13

Pleura of the Lungs

6.2K
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
6.2K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

614
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
614
Pleural Effusion I: Introduction01:25

Pleural Effusion I: Introduction

3.8K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
3.8K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K
Pneumothorax-II01:27

Pneumothorax-II

863
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Zhongguo fei ai za zhi = Chinese journal of lung cancer·2010
Same author

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

The European respiratory journal·2009
Same author

Eighth international mesothelioma interest group.

Oncogene·2007
Same author

Nonmalignant pleural lesions due to environmental exposure to asbestos: a field-based, cross-sectional study.

The European respiratory journal·2005
Same author

Volume-reducing surgery for emphysema: findings in earlier uncontrolled studies.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2004
Same author

Effect of delays on prognosis in patients with non-small cell lung cancer.

Thorax·2003

Related Experiment Video

Updated: Jan 10, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.2K

Pleural malignancies including mesothelioma

G Hillerdal1

  • 1Department of Lung Medicine, Karolinska Hospital, Stockholm, Sweden.

Current Opinion in Pulmonary Medicine
|July 1, 1995
PubMed
Summary

Malignant mesothelioma, often linked to asbestos, may also arise from background exposure. Current treatments focus on symptom relief, with new therapies like local immunotherapy showing promise for early-stage disease.

Area of Science:

  • Oncology
  • Environmental Health

Background:

  • Malignant mesothelioma is primarily caused by occupational asbestos exposure.
  • Emerging evidence suggests background asbestos exposure may also induce mesothelioma.
  • Effective treatments for malignant mesothelioma remain a significant challenge.

Purpose of the Study:

  • To review current and emerging treatment strategies for malignant mesothelioma.
  • To discuss palliative care options for metastatic pleural disease.
  • To identify potential substitutes for injectable tetracycline in pleurodesis.

Main Methods:

  • Literature review of asbestos exposure and mesothelioma.
  • Analysis of therapeutic approaches for early-stage and metastatic mesothelioma.
  • Evaluation of agents used for chemical pleurodesis.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.2K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.6K

Related Experiment Videos

Last Updated: Jan 10, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.2K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.2K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.6K

Main Results:

  • Local interferon treatment shows promise for early-stage mesothelioma.
  • Pleurodesis is key for managing dyspnea in metastatic pleural disease.
  • Talc and doxycycline are leading candidates to replace unavailable injectable tetracycline for pleurodesis.

Conclusions:

  • Novel treatments, including local immunotherapy, offer hope for early mesothelioma.
  • Effective palliation for metastatic disease relies on pleurodesis.
  • The choice of agent for pleurodesis is evolving, with talc and doxycycline as frontrunners.